A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.

NCT01236144 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

113

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukaemia
High Risk Myelodysplastic Syndrome

Interventions

DRUG: Plerixafor
DRUG: AC220
DRUG: Ganetespib

Sponsor

Cardiff University

Collaborators

[object Object]
[object Object]